Cross-Target Docking of GPX4 and SLC7A11 Inhibitor Candidates Against FSP1 in KRAS-Mutant Colorectal Cancer: Dual and Triple Pathway Leads
This study identifies JKE-1674 and PipAryl_005 as promising multi-pathway inhibitor candidates for KRAS-mutant colorectal cancer that exhibit predicted dual or triple activity against GPX4, SLC7A11, and FSP1 through cross-target docking and computational profiling, warranting further experimental validation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer cells are notorious for their ability to survive treatments that should kill them. One promising strategy to defeat them is a form of cell death called ferroptosis. Unlike other types of cell death that involve the cell simply shutting down, ferroptosis is a violent, iron-driven explosion. It happens when the cell's internal machinery fails to clean up toxic fats, causing the cell membrane to rust and rupture from the inside. For years, scientists focused on blocking a specific protein called GPX4, which acts as the cell's primary rust remover. However, cancer cells are clever; they have found a backup plan. In certain aggressive tumors, particularly those with a specific genetic mutation known as KRAS, the cells activate a second defense system. This system uses a different protein, called FSP1, to neutralize the toxic fats without needing the same resources as the first system. If researchers only block the first defense, the cancer simply switches to the second and keeps growing. To truly stop these stubborn tumors, scientists need to find a way to disable both defenses at once, or perhaps even a third one that helps the cell import the materials needed to build its defenses.
In a recent study, a researcher set out to find a single molecule capable of attacking these multiple survival routes in colorectal cancer. The work began with a collection of eleven different chemical compounds. Some of these were already known to block the first defense system (GPX4) or a third system (SLC7A11), while others were newly designed from scratch to look like the natural fuel the second defense system uses. The researcher did not mix these chemicals with cancer cells in a lab dish. Instead, they used powerful computer simulations to see how well each molecule would fit into the tiny, three-dimensional pockets of the FSP1 protein. This protein was recently revealed in high detail by X-ray crystallography, providing a precise map of its structure. The computer program placed each of the eleven molecules into the protein's active sites to see how tightly they would bind, much like testing different keys in a lock to see which ones turn.
The results of this digital screening were surprising. Two of the compounds, which were originally designed to target the first defense system, showed an unexpected ability to fit perfectly into the second system's lock. One of these, named JKE-1674, was predicted to bind to the FSP1 protein with a strength nearly equal to the best known inhibitor currently available. Even more striking was a compound called PipAryl_005. This molecule was originally designed to block the third system, yet in the simulation, it fit into the FSP1 protein even more tightly than the reference inhibitor. This suggests that PipAryl_005 might be a "triple threat," capable of disabling all three of the cancer cell's major defense pathways simultaneously. The study also tested several new, custom-built molecules. While some of these showed promise, the researchers found that a few of the most promising-looking candidates contained chemical structures that could react unpredictably with other parts of the body. By running advanced quantum calculations, they confirmed that these specific structures have genuine redox liability, meaning they may act as FSP1 substrates rather than inhibitors, and therefore require further counter-screening before they can be considered safe drug candidates.
The study concludes that while the computer models are highly encouraging, they are not a final proof of life-or-death effectiveness. The molecules JKE-1674 and PipAryl_005 have passed the digital test, showing they can physically fit into the target protein better than many existing drugs. However, the researchers emphasize that these are still just predictions. The next step is to move from the computer screen to the laboratory bench. Scientists must now perform real-world experiments to see if these molecules actually stop the FSP1 protein from working in a test tube and, eventually, in living cells. If these simulations hold true, the discovery of a single compound that can strike at multiple cancer defense lines at once could offer a new way to treat the most difficult forms of colorectal cancer, turning a survival mechanism into a fatal weakness.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.